Randomized Controlled Trial to Evaluate Personalized Prediction and Adaptation Tools in Psychotherapy

April 27, 2021 updated by: Prof. Dr. Wolfgang Lutz, University of Trier

Randomized Controlled Trial to Evaluate the Effects of Psychometric Feedback on Treatment Outcome and Its Mediators and Moderators in Outpatient Psychotherapy

The research project investigates in a randomized controlled trial the effectiveness as well as moderating and mediating factors of psychometric feedback to therapists. In the intended study a total of 423 patients, who applied for a cognitive-behavioral therapy at the psychotherapy clinic of the University Trier and suffer from a depressive and/or an anxiety disorder (SCID-interviews), will be included. The patients will be randomly assigned either to one therapist as well as to one of two intervention groups (CG, IG2). An additional intervention group (IG1) will be generated from an existing archivale data set via propensity score matching. Patients of the control group (CG; n = 85) will be monitored concerning psychological impairment but therapists will not be provided with any feedback about the patients assessments. In both intervention groups (IG1: n = 169; IG2: n = 169) the therapists are provided with feedback about the patients self-evaluation in a computerized feedback portal. Therapists of the IG2 will additionally be provided with clinical support tools, which will be developed in this project, on the basis of existing systems. Therapists will also be provided with a personalized treatment recommendation based on similar patients (Nearest Neighbors) at the beginning of treatment.

Besides the general effectiveness of feedback and the clinical support tools for negatively developing patients, further mediating and moderating variables on this feedback effect should be examined: treatment length, frequency of feedback use, therapist effects, therapist's experience, attitude towards feedback as well as congruence of therapist's and patient's evaluation concerning the progress.

Additional procedures will be implemented to assess treatment adherence as well as the reliability of diagnosis and to include it into the analyses.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary objective of the current project is to investigate several questions of feedback research in psychotherapy with a cluster randomized controlled trial (RCT) with two feedback groups (IG1: Feedback; IG2: Feedback plus CSTs) and one CG with repeated measurements. IG1 will be generated from an existing archival data set via propensity score matching. It adds to previous feedback research a stricter design by investigating another repeated measurement CG as well as a stricter control of treatment integrity. It also includes a structured clinical interview (SCID) and controls for comorbidity (within depression and anxiety). Furthermore, a more severely impaired patient sample is studied and an international outcome instrument is used, which is also often applied in outpatient centers in Germany. This study also investigates the above described moderators (attitudes towards, use of the feedback system, diagnoses) and mediators (therapists' awareness of negative change and treatment length) in a comprehensive model and in one study.

Therefore, the research questions are:

Main questions:

H1: NOT patients in the feedback condition (IG1) show on average better treatment outcome than NOT patients in the CG.

H2: NOT patients in the IG2 (+CSTs) show on average better treatment outcomes than NOT patients of the IG1 (no CSTs but psychometric feedback).

Secondary questions concerning moderators and mediators:

H3: The positive impact of feedback for NOT patients is moderated through the usage of the feedback system and/or the attitudes of the therapist towards feedback.

  • H3a: The more frequently and the longer feedback is used, the more aware are therapists for negative change.
  • H3b: The more positive the therapists' attitudes towards, the more aware are therapists for negative change.
  • H3c: The effects of feedback on patient outcomes do not differ between diagnostic groups (depression and anxiety).

H4: The positive impact of feedback for NOT patients is mediated through therapists' awareness of negative change as well as treatment length

  • H4a: The positive impact of feedback for NOT patients is mediated by the therapists' awareness of negative developments of patients.
  • H4b: The positive effect of therapists' awareness on treatment outcome is mediated by treatment length (number of sessions).

It is assumed that feedback raises therapists' awareness of negative change. This increased awareness could directly improve treatment outcome through a respective treatment adaption. Given the finding that NOT patients tend to have longer treatments when therapists receive feedback, this effect of increased awareness on treatment outcome could be mediated through treatment length. Accordingly, the essential adaption after being aware of a negative progress would be a higher number of sessions which gives NOT patients more time to improve. However, other adaptions than an increased treatment length are possible and could directly enhance treatment outcome. Regarding the above described moderators it is assumed that the amount of feedback induced awareness as well as the positive effect of feedback on outcome is potentially influenced by therapists' attitude towards feedback, the usage of the feedback system and diagnoses.

Furthermore, effects of feedback are controlled for the following potential influence factors: treatment integrity (adherence, competence), comorbidity, initial impairment, clinical experience as well as experience with the feedback system, non-psychometric feedback and therapist effects (Level 2 variable).

To answer these questions, the following treatment and CSTs will be studied in the outpatient clinic at the University of Trier:

  • Control group (CG): Treatment with continuous assessments but without computer based feedback to therapists.
  • Intervention group 1(IG1): Treatment with continuous assessments including computer based feedback to therapists after each session. This group is a matched sample.
  • Intervention group 2(IG2): Treatment with continuous assessments including computer based feedback to therapists after each session including an alarm for NOT patients and the provision of CST for NOT patients.

Study Type

Interventional

Enrollment (Actual)

423

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Rheinland-Pfalz
      • Trier, Rheinland-Pfalz, Germany, 54296
        • University of Trier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • One anxiety and/or depressive disorder (ICD-10: F32, F33, F40, F41, F42, F43)
  • At least 3 treatment sessions

Exclusion Criteria:

  • Organic, including symptomatic mental disorders (ICD-10: F00-F09)
  • Mental and behavioral disorders due to psychoactive substances (ICD-10: F10-F19)
  • Schizophrenia, schizotypal, and delusional disorders (ICD-10: F20-F29)
  • Acute suicidality

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Cognitive Behavior Therapy
Cognitive Behavioral Therapy without psychometric Feedback.
Behavioral: Cognitive Behavior Therapy
Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
EXPERIMENTAL: CBT plus Feedback
Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
Behavioral: CBT plus Feedback
Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI & OQ-30), interpersonal functioning (IIP-32 & OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
EXPERIMENTAL: CBT plus Feedback plus CST
Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
Behavioral: CBT plus Feedback plus CST
Additional to the intervention group "CBT and Feedback" therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in 11-item Short version of Hopkins' Symptom Checklist (HSCL-11; Lutz, Tholen, Schürch, & Berking, 2006)
Time Frame: through study completion, an average of 50 weeks
The mean of the HSCL-11 is used as the main outcome measure administered before each session.
through study completion, an average of 50 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Outcome Questionnaire (OQ-30; Lambert et al., 1996)
Time Frame: through study completion, an average of 50 weeks
The mean of the OQ-30 is used as the secondary outcome measure administered every fifth session.
through study completion, an average of 50 weeks
Change in Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer, & Williams, 2001)
Time Frame: through study completion, an average of 50 weeks
The sum of the PHQ-9 is used as the secondary outcome measure administered every fifth session.
through study completion, an average of 50 weeks
Change in Generalized Anxiety Disorder (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006)
Time Frame: through study completion, an average of 50 weeks
The sum of the GAD-7 is used as the secondary outcome measure administered every fifth session.
through study completion, an average of 50 weeks
Change in the Brief Symptom Inventory (BSI; Franke, 2000)
Time Frame: through study completion, an average of 50 weeks
The GSI of the BSI is used as a secondary outcome measure administered at the beginning and the end of treatment
through study completion, an average of 50 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Trier

Collaborators

German Research Foundation

Investigators

  • Principal Investigator: Wolfgang Lutz, Prof. Dr., University of Trier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 15, 2017

Primary Completion (ACTUAL)

October 15, 2019

Study Completion (ACTUAL)

May 1, 2020

Study Registration Dates

First Submitted

March 30, 2017

First Submitted That Met QC Criteria

April 4, 2017

First Posted (ACTUAL)

April 11, 2017

Study Record Updates

Last Update Posted (ACTUAL)

April 28, 2021

Last Update Submitted That Met QC Criteria

April 27, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • LU 660/10-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Feedback, Psychological

Clinical Trials on Cognitive Behavior Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe